In a crossover study conducted with eight uremic patients maintained on hemodialysis, the Authors compared the effects of heparin (100 IU/kg at the start of dialysis) and defibrotide (400 mg at the start, repeated at 2 hours of ongoing dialysis) on the parameters of blood coagulation (VIII:C, AT III, TAT, PC antigen and activity, PS, and FPA), each being assessed before dialysis and at 2, 3 and 4 hours of the ongoing procedure. Heparin-assisted dialysis resulted in a significant rise of VIII:C and AT III; with defibrotide, instead, there was evidence of thrombin activation (increased FPA and TAT). PC levels were raised with both dialysis modalities; however, PC activity and PS levels were increased only in defibrotide-assisted dialysis. There were no adverse reactions or evidence of fibrin formation. These results confirm the antithrombotic activity of defibrotide in the course of dialysis and indicate that this action is independent of thrombin neutralization.
DavisJ.W., McFieldJ.R., PhillipsP.L., GrahamB.A.Effects of exogenous urea, creatinine and guanidinsuccinic acid on human platelet aggregation in vitro.Blood1972; 39: 388–97.
2.
HorowitzH.I., SteinI.M., CohenB.D., WhiteJ.G.Further studies on the platelet inhibitory effect of guanidinsuccinic acid: its role in uremic bleeding.Amer J Med1970; 49: 336–45.
3.
RabinerS.F., MolinarF.The role of phenol and phenolic acid on the thrombocytopathy and defective platelet aggregation of patients with renal failure.Amer J Med1970; 49: 346–51.
4.
RemuzziG., CavenaghiA.E., MeccaG., DonatiM.B., De GaetanoG.Prostacyclin-like activity and bleeding in renal failure.Lancet1977; 2: 1195–7.
5.
LeithnerC., WinterM., SilbauerK., WagnerO., PinggeraW., SinzingerH.Enhanced prostacyclin availability of blood vessels in uraemic patients and in rats. In: RobinsonB.H.B., HawkinsJ.B., eds. Dialysis, transplantation the 15th Congress of EDTA.London: Pitman, 1978; 418–22.
6.
TanakaH., UminotoK., IzumiN., MaekawaT., KishimotoT., MaekawaM.Platelet cyclo-oxygenase in hemodialysis patients: what suppresses its activity?Kidney Int1985; 28: 357.
7.
RemuzziG., BenigiA., DodesiniP.Reduced platelet thromboxane formation in uremia: evidence for a functional cyclo-oxygenase defect.J Clin Invest1983; 71: 762–8.
8.
SmithM.C., DunnM.J.Impaired thromboxane production in renal failure.Nephron1981; 29: 133–7.
9.
RemuzziG., MeccaG., MarchesiD.Platelet hyperaggregability and the nephrotic syndrome.Thromb Res1979; 16: 345–54.
10.
ThompsonA.R.Factor XII and other hemostatic protein abnormalities in nephrotic syndrome patients.Thromb Haemost1982; 48: 27–32.
11.
LevinM., NokesT.J.C., HardistyR.M., BarratT.M.Spontaneous platelet aggregation in the nephrotic syndrome.Intern J Pediatric Nephrology1981; 2: 147.
12.
EkbergM., NilssonI.M.Factor VIII and glomerulonephritis.Lancet1975; 1: 1111–3.
13.
CornelliU., NazzariM.Defibrotide — an overview of clinical pharmacology and early clinical trials.Seminars in Thromb Hemost1988; suppl 14: 64–74.
14.
BucciantiG., ValentiG., LorenzM., CresseriD., StradaE., NazzariM.Kinetics of anti-Xa activity during combined defibrotide-heparin administration in hemodialysis.Int J Artif Organs1990; 13(7): 416–20.
BoyerC., WolfM., AmiralJ., MeyerD., LarrieuM.Y.A new method for estimation of Protein C by ELISA.Thromb Res1984; 36: 579–89.
21.
AmiralJ.Immunoassays for measurement of Protein S.Stago Immunological Research1986.
22.
SoriaJ., SoriaC., RickevaertJ.J.A solid phase immunoenzymological assay for the measurement of the human FPA.Thromb Res1980; 20: 425–35.
23.
KnudsenF., DybergJ.Platelets and AT III in uremia.Scand J Clin Lab Invest1985; 45: 341–7.
24.
GunnarsonB., AsabaH., DavidsonnS., WilhelmsonS., BergstromJ.The effects of three different heparin regimes on heparin concentrations in plasma and fibrin formation in dialyzers.Clin Nephrol1981; 15: 135–42.
25.
SuzukiK., NishiokaJ., HashimotoS.Protein C inhibitor.J Biol Chem1983; 258: 163.
26.
BertinaR.M.The control of hemostasis: Protein C and Protein S.Biomed Progress1989; 4.
27.
SorensenP.J., KnudsenF., NielsenH., DyerbergK.Protein C in uremia.Thromb Res1989; 54: 301–10.
28.
O'ConnorN.T.J., BroekmanA.W., BertinaR.M.Protein C values in coronary artery disease.Br Med J1984; 289: 1192.
29.
ViganòS., MannucciP.M., D'AngeloA.Protein C antigen is not an acute phase reactant and is often high in ischemic heart disease and diabetes.Thromb Haemost1984; 52: 263–6.
30.
MeadeT.W., StirlingY., WilkesH., MannucciP.M.Effects of oral contraceptives and obesity on Protein C antigen.Thromb Haemost1985; 53: 198–9.
31.
Pabinger-FaschingI., LechnerK., NiessnerH., SchmidtP., BalzarE.High levels of plasma protein C in nephrotic syndrome.Throm Haemost1984; 53: 5–7.
32.
CosioF.G., HarkerC., BatardM.A., BrandtJ.T., GriffinJ.H.Plasma concentration of the natural anticoagulant protein C and protein S in patients with proteinuria.J Lab Clin Med1985; 106: 218–22.
33.
MannucciP.M., D'AngeloA., ViganòS.Decrease and rapid recovery of protein C, an anticoagulant protein, after plasma exchange.Transfusion1986; 26: 156–8.
34.
MannucciP.M., ViganòS.Deficiences of protein C, an inhibitor of blood coagulation.Lancet1982; 2: 463–7.
35.
SwartzR.D., PortF.K.Preventing hemorrhage in high-risk hemodialysis: regional versus low dose heparin.Kidney Intern1979; 16: 513–8.
36.
TurneyJ.H., FewellM.R., WilliamsL.C., ParsonsV., WestonM.J.Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy.Lancet1980; 2: 219–22.
37.
ZusmanR.M., RubinR.H., CatoA.E., CocchetoD.M., CrowJ.W., Tockoff-RubinN.Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic treatment.New Engl J Med1981; 304: 934–9.
38.
KnudsenF., NielsenA.H., KornerupH.J., PedersenJ.O., DyerbergJ.Epoprostenol as sole antithrombotic treatment during hemodialysis.Lancet1984; 2: 235–6.
39.
SmithM.C., DanviriyasupK., CrowJ.W.Prostacyclin substitution for heparin in long term hemodialysis.Am J Med1982; 73: 669–78.
40.
HathiwalaS.Dialysis without anticoagulant action of human protein C.Protides Biol Fluids1980; 28: 341–4.
